The company will still provide interpretation-only services, but by adding in-house testing it has dramatically increased its customer base.
The deal will help the Finnish diagnostics company expand its offerings of PCR-based gastrointestinal diagnostic tests.
Devyser recently launched NGS-based tests for cystic fibrosis and the BRCA genes and aims to launch others in oncology, reproductive health, and genetic disease.
The companies intend to bring companion diagnostics through US Food and Drug Administration clearance using ArcherDX's AMP chemistry and Illumina's MiSeqDx.
The grants are strictly for new research, but Rice University scientist David Zhang is always looking for commercialization opportunities with his startup, Searna.
The partners will develop multiplex tests to detect human pathogens in 75 minutes on Grenier's PCR-based Genspeed Test System.
The firm now expects to launch the ePlex in Europe in the first quarter of 2016, after which it will pursue FDA approval.
Researchers followed individuals from more than two-dozen households for a year, tracking self-reported symptoms and respiratory virus DNA in nasal swab samples.
The contract is to further the company's work to develop methodologies aimed at Francisella tularensis, Escherichia coli, and Babesia microti.
NEW YORK (GenomeWeb) — Researchers from Virginia Commonwealth University have developed a method of quantifying multiple nucleic acid targets in a single sample by combining low-cycle-number, target-specific PCR with atomic force microscopy.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.